The role of GSK-3 in myogenesis and recovery of atrophied muscle

N.A.M. Pansters

Research output: ThesisDoctoral ThesisInternal

322 Downloads (Pure)


Loss of muscle mass, also known as muscle atrophy, is prevalent in chronic diseases such as COPD. Due to its limiting effects on daily activities and quality of life, treatment regimens also focus on muscle mass recovery. Research into the GSK-3 protein, which is a negative regulator of muscle mass, shows that muscle mass recovery does not require inhibition of GSK-3 activity as observed during the recovery of atrophied muscle, although complete elimination of GSK-3 enhances the early phase of muscle mass recovery. These results offer insights into the mechanisms underlying muscle mass recovery which can be used to develop drugs specifically aimed at enhancing muscle mass maintenance and recovery in people suffering from chronic diseases.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • Maastricht University
  • Schols, Annemie, Supervisor
  • Langen, Ramon, Co-Supervisor
Award date8 Oct 2015
Place of PublicationMaastricht
Print ISBNs9789462038790
Publication statusPublished - 2015


  • chronic diseases
  • COPD
  • loss of muscle mass
  • treatment

Cite this